Showing results (331-340 of 350) with videos related to

Sort By:
Pageof 35
Tropical Biomedicine|October 10, 2022
Advances in the study of molecular identification technology of Echinococcus speciesR J Zhang, J Z Li, H S Pang, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics|June 15, 2025
[Therapeutic value of visual endoscopic retrograde appendicitis therapy in children with acute suppurative appendicitis]A D Zhang, N Fan, M Z Wang, et al.
Hepatology Communications|September 24, 2021
Detection of Hepatitis B Virus-Host Junction Sequences in Urine of Infected PatientsSelena Y Lin, Yih-Ping Su, Evan R Trauger, et al.
Clinical Pharmacology and Therapeutics|December 31, 2010
Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory reviewP Zhao, L Zhang, J A Grillo, et al.
Lancet (London, England)|August 21, 2016
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialQuan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, et al.
The Review of Scientific Instruments|December 3, 2008
First measurements of the absolute neutron spectrum using the magnetic recoil spectrometer at OMEGA (invited)J A Frenje, D T Casey, C K Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 21, 2018
[Synchronous lymphoma and carcinoma-clinical analyses of 17 patients]Y Y Xiong, Z J Liu, L Chen, et al.
The New England Journal of Medicine|September 8, 2016
Adalimumab in Patients with Active Noninfectious UveitisGlenn J Jaffe, Andrew D Dick, Antoine P Brézin, et al.
Ocular Immunology and Inflammation|July 18, 2018
Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II TrialsHiroshi Goto, Masahiro Zako, Kenichi Namba, et al.
Anais Brasileiros De Dermatologia|December 8, 2024
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in BrazilTania F Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, et al.
Pageof 35